Senexin B
产品说明书
 |
同义名 : | SNX2-1-165; BCD-115 |
| CAS号 : | 1449228-40-3 | |
| 货号 : | A1145598 | |
| 分子式 : | C27H26N6O | |
| 纯度 : | 99%+ | |
| 分子量 : | 450.54 | |
| MDL号 : | MFCD31544331 | |
| 存储条件： |
Pure form Keep in dark place, sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Senexin B is a highly effective, selective and oral Cdk8 / cdk19 inhibitor with IC50 values ranging from 24 to 50 nm. In 8-week-old cb-17 SCID mice, 40 mg / kg senexin B or control reagent was injected intraperitoneally for 5 days, and then subcutaneously for 1 day × 106 human A549 lung cancer cell line, senexin B significantly slowed down tumor growth. In female nude mice with MDA-MB-468 three negative breast cancer (TNBC) cells injected with fat pad in situ, 25 mg/kg Senexin B (i.p.) was pretreated for 5 days a day, and the tumor growth was inhibited effectively and continuously. Senexin B is a highly effective, selective and oral Cdk8 / cdk19 inhibitor. Senexin B showed selectivity for Cdk8 and cdk19, with Kd values of 140 nm and 80 nm, respectively. 1 mm of senexin B was completely dissolved in 20% propylene glycol with a solubility of 50 mm in water. In vitro and in vivo experiments, senexin B in the low nanomolar range inhibited the activity of Cdk8 / 19 in a competitive manner of ATP[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.22mL 0.44mL 0.22mL |
11.10mL 2.22mL 1.11mL |
22.20mL 4.44mL 2.22mL |
| 参考文献 |
|---|